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The aim of this meta-analysis was to provide treatment guidelines for sinonasal neuroendocrine carci-
noma (SNC) by combining all available data in the literature.
A literature search for all studies concerning SNC was performed against the MEDLINE and EMBASE
databases. Available clinical data was normalized, pooled, and statistically analyzed.
A total of 701 cases of SNC were available for analysis, comprising 127 well or moderately differenti-
ated sinonasal neuroendocrine carcinomas (SNEC), 459 sinonasal undifferentiated carcinoma (SNUC) and
115 sinonasal small cell carcinoma (SmCC). Tumor type was the most important predictor of survival,
with a 5-year disease-specific survival (DSS) of 70.2% for SNEC, 35.9% for SNUC and 46.1% for SmCC.
Tumor stage on presentation was of limited value in predicting survival or response to treatment.
Overall, the application of surgery yielded significantly better results (5-year DSS 52.2% versus 30.1%,
p < 0.001). In SNUC, radiotherapy was a beneficial supplement to surgery (5-year DSS 54.7% versus
15.7%, p = 0.027), while radiotherapy as monotherapy performed poorly (5-year DSS 17.9%).
Chemotherapy did not appear to contribute to survival.
Based on these findings, we can conclude that the most important predictors of survival in SNC are dif-
ferentiation grade and the associated choice of treatment modality. In contrast to other head and neck
cancers, tumor staging appears of limited value in predicting survival or deciding on a treatment strategy.
Surgery should be the cornerstone of treatment, supplemented by radiotherapy in poorly differentiated
subtypes (SNUC, SmCC). Chemotherapy does not appear to contribute to survival.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Sinonasal tumors with neuroendocrine differentiation are a rare
group of neoplasms that account for only 5% of all sinonasal
malignancies [1]. A broad distinction is made between tumors of
neuroectodermal origin - esthesioneuroblastoma - and those of
epithelial origin - sinonasal neuroendocrine carcinoma (SNC). Thelatter can be subdivided based on differentiation grade into well,
moderately and poorly differentiated SNC. Poorly differentiated
SNC are further subdivided into a small and large cell variants.
In the literature an ambiguous nomenclature is maintained.
Confusingly, in contrast to well and moderately differentiated
SNC, large cell poorly differentiated SNC are denoted by sinonasal
undifferentiated carcinoma (SNUC) and small cell poorly differen-
tiated SNC by sinonasal small cell carcinoma (SmCC), discounting
their neuroendocrine nature. In order to prevent further ambiguity,
well and moderately differentiated SNC are referred to by their
common abbreviation, SNEC, in this article.
Previous studies have shown tumor behavior to differ markedly
between the various entities of sinonasal tumors with neuroen-
docrine differentiation [2]. For esthesioneuroblastoma a well-
defined treatment strategy is available that, in part due to their
2 T.P. van der Laan et al. / Oral Oncology 63 (2016) 1–9more benign nature, yields reasonable results [3]. However, for
SNC no clear guidelines are available and treatment outcome
remains both variable and poor. Individual studies have shown
large differences in response to treatment and prognosis between
SNEC, SNUC, and SmCC and, more recently, have advocated the
use of multimodality therapy in order to improve survival [4,5].
While valuable, these studies suffer from small sample size due
to the rare nature of these tumors. This makes it hard to estimate
the contribution of individual treatment modalities to treatment
outcome, especially considering the possibility that treatment
response might differ between tumor subtypes.
The aim of this meta-analysis was to provide treatment guide-
lines for SNC by combining all available data concerning factors
influencing treatment response and survival in the literature.Material and methods
A literature search for all clinical research concerning SNC was
performed against the MEDLINE and EMBASE databases. The fol-
lowing combination of search terms was used: ‘neuroendocrine
carcinoma/tumor’, ‘undifferentiated carcinoma/tumor’, ‘small cell
carcinoma/tumor’, ‘oat cell carcinoma/tumor’, or ’carcinoid
(tumor)’ in combination with either ‘nasal’, ‘sinonasal’, ‘paranasal
(sinuses)’, ‘sinus(es)’, ‘ethmoid (sinus)’, ‘frontal (sinus)’, ‘maxillary
(sinus)’ or ‘ sphenoid (sinus)’. Full text copies of all relevant articles
in English were retrieved and checked for references. When avail-
able, English abstracts of non-English articles containing relevant
data were included. Articles and abstracts not containing (original)
clinical data or compound data were discarded. The following vari-
ables were extracted from the remainder: age at diagnosis, gender,
tumor type, tumor stage, ectopic hormone production, treatment
and survival. If not reported, the tumor stage was determined
using the TNM staging system. Duplicate cases were removed.
Cases were divided in two cohorts in order to allow for analysis
of trends over time: those reported before 2006 and those reported
thereafter, effectively dividing the number of cases per cohort in
two equal proportions. Statistical analysis was performed using
IBM SPSS Statistics 22 for Microsoft Windows (Armonk, NY). Age
was compared using the median test. Categorical data were ana-
lyzed using the exact chi-square test. Survival data were calculatedTable 1
Patient characteristics of sinonasal neuroendocrine carcinoma. Bold numbers represent si
Variable All (n = 701) SNEC
Age (median, range) 53 (12–89) 50 (1
Gender (male, %) 378 (64.6) 70 (5
Tumor stage (%)
Stage I 25 (5.0) 8 (10
Stage II 38 (7.6) 15 (1
Stage III 61 (12.2) 10 (1
Stage IV 375 (75.0) 44 (5
Stage IVA 116 (23.3) 16 (2
Stage IVB 147 (29.5) 22 (2
Stage IVC 22 (4.4) 2 (2.6
Treatment (%)
Surgery 56 (10.3) 22 (2
Radiotherapy 52 (9.5) 4 (4.4
Chemotherapy 12 (2.2) 0 (0.0
Surgery & Radiotherapy 88 (16.1) 22 (2
Surgery & Chemotherapy 12 (2.2) 3 (3.3
Surgery & Radiotherapy & Chemotherapy 150 (27.5) 16 (1
Radiotherapy & Chemotherapy 138 (25.3) 21 (2
Palliative care 38 (7.0) 2 (2.2
Median disease specific survival 36 (27–45) 174 (
Median overall survival 32 (25–39) 120 (
SNEC, well or moderately differentiated sinonasal neuroendocrine carcinoma; SNUC, sinusing the Kaplan-Meier estimator. Uni- and multivariate analysis
was performed using the Cox proportional hazards model (enter
method). Alpha was set at 0.05. Reported confidence intervals are
for 95% probability.Results
After discarding articles not including original clinical data or
compound data, a total of 171 articles remained available for anal-
ysis [4–174]. Full text copies were available for 167 of these.
Abstracts containing clinical data were included for five articles
not in English [39,73,92,159,162] and one in English [168], yielding
a total of 701 cases.
Patient characteristics
Patient characteristics are presented in Table 1. Most cases were
classified as SNUC (459, 65.5%), followed by SNEC (127, 18.1%) and
SmCC (115, 16.4%). The median age on presentation for all SNC was
53 years (range 12–89). Overall there was a male gender predilec-
tion (64.6%). The tumor stage on presentation was stage IV in 75.0%
of cases. However, this distribution significantly differed amongst
tumor types, with SNEC presenting with stage IV in 57.1% of cases,
SmCC in 70.4% and SNUC in 80.6% (p < 0.001). It was not possible to
reliably infer the original tumor location from the available data as
most patients presented with advanced disease.
Treatment consisted of multimodality therapy in the majority
of cases treated with curative intent (73.7%). Overall, radiotherapy
was the most frequently employed modality in these patients with
84.3%, followed by 61.4% for chemotherapy and 60.2% for surgery.
Combination therapy most often consisted of trimodality therapy
(38.7%) or a combination of radiotherapy and chemotherapy
(36.6%). The combination of surgery and radiotherapy was less
often applied (22.7%). Only a small minority of patients was treated
with a combination of surgery and chemotherapy (3.1%). There
were significant differences in choice of treatment between sub-
types. Compared to SNUC, SNEC and SmCCwere more often treated
with surgery as monotherapy (4.3% versus 24.4% and 17.4% respec-
tively, p < 0.001). SNUC were more often treated with radiotherapy
as monotherapy compared to SNEC and SmCC (12.4% versus 4.4%gnificant P-values (P < 0.05).
(n = 127) SNUC (n = 459) SmCC (n = 115) P-value
3–84) 53 (12–88) 56 (16–89) 0.023
6.9) 239 (68.7) 69 (60.5) 0.038
.4) 8 (2.5) 9 (9.2) 0.002
9.5) 10 (3.1) 13 (13.3) <0.001
3.0) 45 (13.8) 6 (6.1) 0.125
7.1) 262 (80.6) 69 (70.4) <0.001
0.8) 67 (20.7) 33 (33.7) 0.025
8.6) 104 (32.2) 21 (21.4) 0.116
) 17 (5.2) 3 (3.1) 0.480
4.4) 15 (4.3) 19 (17.4) <0.001
) 43 (12.4) 5 (4.6) 0.011
) 7 (2.0) 5 (4.6) 0.080
4.4) 54 (15.6) 12 (11.0) 0.033
) 2 (0.6) 7 (6.4) 0.006
7.8) 110 (31.7) 24 (22.0) 0.015
3.3) 85 (24.5) 32 (29.4) 0.546
) 31 (8.9) 5 (4.6) 0.044
69–279) 28 (23–33) 22 (6–38) <0.001
55–185) 25 (21–29) 22 (14–30) <0.001
onasal undifferentiated carcinoma; SmCC, sinonasal small cell carcinoma.
Table 2
Univariate analysis of factors influencing the disease-specific survival of sinonasal
neuroendocrine carcinoma. Bold numbers represent significant P-values (P < 0.05).
Factor OR (95% CI) P-value
Age 1.009 (1.001–1.017) 0.019
Gender (male as reference) 0.874 (0.660–1.159) 0.351
Tumor type
T.P. van der Laan et al. / Oral Oncology 63 (2016) 1–9 3and 4.6% respectively, p = 0.011), while SNEC were more frequently
treated with surgery combined with radiotherapy (24.4% versus
15.6% for SNUC and 11.0% for SmCC, p = 0.033). SNUC was rarely
managed with a combination of surgery and chemotherapy (0.6%
versus 3.3% for SNEC and 6.4% for SmCC, p = 0.006), but more often
treated with a trimodality approach compared to the other groups
(31.7% versus 17.8% for SNEC and 22.0% for SmCC, p = 0.015).SNEC 1 (reference)
SNUC 2.601 (1.783–3.794) <0.001
SmCC 2.410 (1.539–3.774) <0.001
Tumor stage
Stage I 1 (reference)
Stage II 2.152 (0.781–5.930) 0.139
Stage III 3.672 (1.425–9.460) 0.007
Stage IV 3.663 (1.462–9.180) 0.006
Stage IVA 2.210 (0.871–5.607) 0.095Ectopic hormone production
Ectopic hormone production was described in ten cases (1.4%)
[9,15,29,57,75,91,110,172]. These cases concerned patients with
SNEC or SmCC with elevated levels of ACTH, beta-MSH, calcitonin,
serotonin or ADH.Stage IVB 3.050 (1.224–7.597) 0.017
Stage IVC 7.612 (2.695–21.499) <0.001
Treatment (decoupled, no as reference)
Surgery 0.521 (0.400–0.677) 0.000
Radiotherapy 0.898 (0.631–1.279) 0.898
Chemotherapy 1.243 (0.944–1.636) 0.121
Treatment
Surgery 1 (reference)
Radiotherapy 2.261 (1.329–3.847) 0.003
Chemotherapy 6.182 (2.803–13.633) <0.001
Surgery & Radiotherapy 0.779 (0.444–1.366) 0.383
Surgery & Chemotherapy 1.810 (0.801–4.090) 0.154
Surgery & Radiotherapy
& Chemotherapy
1.052 (0.638–1.735) 0.905
Radiotherapy & Chemotherapy 1.712 (1.050–2.791) 0.031
Palliative care 15.769 (7.408–33.567) <0.001
OR, odds ratio; CI, confidence interval; SNEC, well or moderately differentiated
sinonasal neuroendocrine carcinoma; SNUC, sinonasal undifferentiated carcinoma;
SmCC, sinonasal small cell carcinoma.Survival
The median disease-specific survival (DSS) for SNEC was
36 months (CI 27–45) and the overall survival 32 months (CI,
25–39). Fig. 1A displays the influence of tumor type on DSS. SNEC
performed significantly better with a 5-year DSS of 70.2%
compared to 35.9% for SNUC and 46.1% for SmCC (p < 0.001). There
was no significant difference between the 5-year DSS of SNUC and
SmCC (p = 0.792). Comparable results were produced by the
univariate analysis presented in Table 2. Overall, tumor stage did
not significantly affect survival as shown in Fig. 1B. Similar results
were produced when correcting for tumor type. The univariate
analysis yielded varying results, with no significant difference in
odds ratio (OR) between stage IVA and stage I disease (CI OR,
0.0871–5.607, p = 0.095).
Fig. 2 displays an exploratory analysis of the influence of differ-
ent treatment modalities on DSS. Overall, only surgery had a signif-
icant effect on 5-year DSS with 52.2% for patients treated with
surgery versus 30.1% for those without (p < 0.001).
While there was a trend favoring surgery in SNEC, no significant
difference could be observed (p = 0.077). Radiotherapy did not
yield better results in these patients (p = 0.199), while the applica-
tion of chemotherapy was associated with a significantly unfavor-
able outcome (5-year DSS of 55.7% versus 82.2%, p = 0.029).
Both surgery and radiotherapy were associated with signifi-
cantly better outcome in patients with SNUC (5-year DSS of
42.2% versus 26.9%, p < 0.001, and 38.0% versus 10.6%, p = 0.008,
respectively). The application of chemotherapy did not improve
survival in these patient (5-year DSS of 36.6% versus 33.3%,
p = 0.782).Fig. 1. Disease-specific survival (DSS) of sinonasal neuroendocrine carcinoma (SNC) pe
sinonasal neuroendocrine carcinoma; SNUC, sinonasal undifferentiated carcinoma; SmCWhile not significant, surgery appeared to have a beneficial
effect on treatment outcome in patients with SmCC (5-year DSS
of 53.9% versus 32.0%, p = 0.077), while no difference in outcome
could be observed for radiotherapy and chemotherapy (5-year
DSS of 50.1% for patients treated with radiotherapy versus 39.6%
for those without, p = 0.287 and 42.6% for patients treated
with chemotherapy versus 52.9% for those without, p = 0.287
respectively).
A multivariate analysis of the influence of treatment (combina-
tions) correcting for age on diagnosis and tumor stage on presenta-
tion is presented in Table 3. Patients with SNEC treated withoutr tumor type, stage and publication date. SNEC, well or moderately differentiated
C, sinonasal small cell carcinoma.
Fig. 2. Disease-specific survival of sinonasal neuroendocrine carcinoma (SNC) per tumor type and treatment modality. The straight line represents the cohort in which the
treatment modality was applied. Survival in months. SNEC, well or moderately differentiated sinonasal neuroendocrine carcinoma; SNUC, sinonasal undifferentiated
carcinoma; SmCC, sinonasal small cell carcinoma.
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11.464, CI 1.125–116.796, p = 0.039). No advantage from multi-
modality therapy could be inferred from this analysis. For SNUC,
patients treated with a combination of surgery and radiotherapy,
with or without chemotherapy, had better outcome than those
treated with surgery alone (OR 0.337, CI 0.0125–0.908, p = 0.032
and OR 0.368, CI 0.147–0.921, p = 0.033 respectively). Chemother-
apy as monotherapy yielded a significantly higher OR in patientswith SmCC (6.964, CI 1.104–43.930), while none of the other treat-
ment (combinations) significantly differed from surgery as
monotherapy.
5-Year DSS estimates per tumor type and treatment (combina-
tion) are presented in Table 4. Overall, the highest 5-year DSS was
observed for the combination of surgery and radiotherapy (64.0%).
For SNEC surgery as monotherapy produced the most favorable
results (5-year DSS 83.3%). SNUC and SmCC responded best to a
Table 3
Multivariate analysis of factorsa influencing the disease-specific survival of sinonasal
neuroendocrine carcinoma treated with curative intent per tumor type. Bold numbers
represent significant P-values (P < 0.05).
Factor OR (95% CI) P-value
Well or moderately differentiated sinonasal neuroendocrine carcinoma
Surgery 1 (reference)
Radiotherapy – –
Chemotherapy – –
Surgery & Radiotherapy 4.604 (0.514–41.212) 0.172
Surgery & Chemotherapy 6.950 (0.355–135.961) 0.201
Surgery & Radiotherapy & Chemotherapy 4.804 (0.370–62.430) 0.230
Radiotherapy & Chemotherapy 11.464 (1.125–116.796) 0.039
Sinonasal undifferentiated carcinoma
Surgery 1 (reference)
Radiotherapy 0.643 (0.254–1.632) 0.353
Chemotherapy 1.644 (0.443–6.105) 0.458
Surgery & Radiotherapy 0.337 (0.125–0.908) 0.032
Surgery & Chemotherapy 3.164 (0.359–27.890) 0.300
Surgery & Radiotherapy & Chemotherapy 0.368 (0.147–0.921) 0.033
Radiotherapy & Chemotherapy 0.471 (0.185–1.200) 0.115
Sinonasal small cell carcinoma
Surgery 1 (reference)
Radiotherapy 3.669 (0.677–19.900) 0.132
Chemotherapy 6.964 (1.104–43.930) 0.039
Surgery & Radiotherapy 0.529 (0.123–2.278) 0.393
Surgery & Chemotherapy 1.057 (0.239–4.669) 0.942
Surgery & Radiotherapy & Chemotherapy 0.811 (0.234–2.806) 0.741
Radiotherapy & Chemotherapy 1.078 (0.370–3.146) 0.890
OR, odds ratio; CI, confidence interval. Reported odds ratios for patient dying of
disease.
a Not shown but included in the models are the factors age and tumor stage. Both
of which did not reach significance in any of the models.
T.P. van der Laan et al. / Oral Oncology 63 (2016) 1–9 5combination of surgery and radiotherapy (5-year DSS of 54.7% and
71.3% respectively).
Trends over time
As shown in Fig. 1C, cases reported after 2006 show improved
outcome compared to those reported before this date (5-year
DSS of 50.4% versus 36.1%, p < 0.001). This trend was present for
all tumor types, although only SNUC remained significant after
sub-analysis (p = 0.001). Patients with SNUC, reported before
2006, were more often treated with radiotherapy as monotherapy
(21.1% versus 4.3%), while those reported after 2006 were more
often treated with a combination of surgery and radiotherapy with
or without chemotherapy (65.9% versus 40.6%).Discussion
Synopsis
This study offers the most comprehensive overview of knowl-
edge concerning SNC available today by pooling all available casesTable 4
5-year disease-specific survival estimates of sinonasal neuroendocrine carcinoma per tum
Treatment All
All 43.9 (2.8)
Surgery 52.7 (8.3)
Radiotherapy 22.7 (7.3)
Chemotherapy 0.0 (0.0)
Surgery & Radiotherapy 64.0 (6.4)
Surgery & Chemotherapy 30.0 (14.0)
Surgery & Radiotherapy & Chemotherapy 47.0 (5.6)
Radiotherapy & Chemotherapy 36.3 (5.4)
SNEC, well or moderately differentiated sinonasal neuroendocrine carcinoma; SNUC, sinpublished in the literature. It is clear from our data, that prognosis
is primarily determined by histological subtype and thus differen-
tiation grade, rather than by TNM classification. Overall, SNEC have
a reasonable prognosis, with a 5-year DSS of about 70%, while
SNUC and SmCC perform poorly with a 5-year DSS of approxi-
mately 40%. Surgery should be the cornerstone of treatment as it
was associated with improved outcome, regardless of its combina-
tion with other treatment modalities or tumor subtype. Postoper-
ative radiotherapy should be applied in patients with SNUC or
SmCC.
Classification
As noted in the introduction, the nomenclature of SNC applied
in the literature is both confusing and ambiguous. This is a com-
mon problem concerning neuroendocrine carcinoma of the head
and neck, as evidenced by the diverse terminology used for their
more common laryngeal counterparts [175]. In 2002, Mills already
recognized the similarities between (the subtypes of) neuroen-
docrine carcinoma of the head and neck of different locations
and suggested that SNUC was probably best recognized as the
equivalent of the large cell neuroendocrine carcinoma of the larynx
[176]. While similar tumors in different locations may behave dif-
ferently and require a different treatment approach, certain simi-
larities are lost in translation. This is crucial problem, as it is
clear from our data that the histological diagnosis is the single
most important factor influencing response to treatment and
survival.
In order to solve this problem in laryngeal neuroendocrine car-
cinoma (LNC), Lewis et al. proposed to adopt the classification sys-
tem of pulmonary neuroendocrine carcinoma, in which
neuroendocrine carcinoma are classified based on differentiation
grade [175]. We suggest extending this classification to SNC as
well, additionally labeling poorly differentiated SNC A for small
and B for large cell features (Table 5). Unifying the classification
system for neuroendocrine carcinoma of the head and neck would
yield a more intuitive way of thinking about these neoplasms and
prevent relevant data from not being taken into consideration due
to semantic deficiencies.
Tumor stage on presentation
Sinonasal malignancies often present at an advanced stage due
to the lack of disconcerting symptoms. This reduces the value of
the TNM classification system (or any other classification system
for that matter) in predicting prognosis and aiding in treatment
selection. This holds true for SNC as well, with 75.0% of patients
presenting with stage IV disease. In patients presenting with early
stage disease the TNM classification remains of poor value as uni-
variate analysis revealed that patients with stage III disease had a
higher OR for dying of disease compared to patients with stage IVA
disease (3.672 versus 2.210), while no significant difference in OR
could be observed between stage I and stage IVA disease. A similaror type and treatment (combination) of patients treated with curative intent.
SNEC SNUC SmCC
70.2 (5.9) 35.9 (3.5) 46.1 (5.9)
83.3 (9.0) 15.7 (13.1) 52.1 (13.9)
100.0 (–) 17.9 (7.1) 0.0 (0.0)
– 0.0 (0.0) 0.0 (0.0)
77.9 (10.2) 54.7 (9.2) 71.3 (14.1)
66.7 (27.2) 0.0 (0.0) 28.6 (17.1)
73.8 (13.8) 40.2 (6.8) 57.6 (11.6)
39.2 (13.5) 40.2 (6.8) 39.9 (10.9)
onasal undifferentiated carcinoma; and SmCC, sinonasal small cell carcinoma.
Table 5
Classification schemes for sinonasal neuroendocrine carcinoma.
Legacy terminology Common abbreviation Differentiation grade Cell size Proposed terminology
Carcinoid SNEC Well – Grade I
Atypical carcinoid SNEC Moderate – Grade II
Small cell (neuroendocrine) carcinoma SmCC Poor Small Grade IIIA
Sinonasal undifferentiated carcinoma SNUC Poor Moderate to large Grade IIIB
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propensity for recurrence and early distant metastasis [177]. Due
to the nature of the data and the confusing outcome of the result-
ing analyses, the relationship between tumor stage on presentation
and survival remains uncertain. However, as patients with limited
disease potentially have a similar prognosis to those with
advanced disease, we think that treatment strategy should not be
influenced by this factor, except in specific cases in which isolated
lesions can be excised and surgical margins evaluated properly.Ectopic hormone production
The incidence of ectopic hormone production is likely higher
than the reported 1.4% due to under-diagnosis and under-
reporting. However, only a small number of patients presented
with clinical features in the form of the associated paraneoplastic
syndrome and it remains unclear whether routine tests should
be incorporated in the work-up of these patients.Treatment and survival
Due to the nature of the study care should be taken in interpret-
ing the resulting analyses. Incomplete data results in some seem-
ingly contradictory figures (e.a. an overall survival estimate that
is lower than the disease-specific survival). However, by including
these data points we utilize the available information to its fullest
and are able to provide estimates that are as close to reality as
possible.
While decoupling the combination of treatment modalities
introduces an obvious bias, Fig. 2 allows for an exploratory analysis
of the contribution of different treatment modalities to treatment
outcome. Combined with the results from the uni- and multivari-
ate analysis, and the 5-year DSS per tumor subtype and treatment
(combination) presented in Table 4 a general pattern can be
observed.
It appears clear that, irrespective of the histological diagnosis,
surgery has a beneficial effect on survival and should be the
cornerstone of any treatment strategy. This is supported by both
the univariate and multivariate analyses in which treatment (com-
binations) incorporating surgery produced the best results with
the exception of four patients with a SNEC who were successfully
treated with radiotherapy as monotherapy. It is unfortunate that
most authors do not make a distinction between well and moder-
ately differentiated SNEC as the former could probably be treated
by surgery alone while the latter may require a more aggressive
approach incorporating postoperative radiotherapy.
Radiotherapy appeared especially beneficial in patients with
SNUC, but only if combined with surgery. In fact, the combination
of surgery and radiotherapy with or without chemotherapy yielded
a significantly lower OR for patients dying of disease in the multi-
variate analysis (0.337, CI 0.125–0.908 and 0.368, CI 0.147–0.921
respectively), making it the de facto treatment strategy for this
group. Radiotherapy as monotherapy performed poorly with the
exception of the four patients mentioned above (5-year DSS of
17.9% for SNUC and 0.0% for SmCC) and should not be performed
in curative setting.No benefit from the application of chemotherapy could be
deduced from our results. Chemotherapy as monotherapy had
the worst 5-year DSS, with no patients surviving regardless of
tumor subtype.
The improvement in treatment outcome over time is best
explained by the shift towards multimodality therapy as advocated
by several authors. Especially the abandonment of radiotherapy as
monotherapy appears to have contributed to improved survival.
Furthermore, the advance of treatment modalities, e.a. the intro-
duction of image guided surgery, could have positively affected
treatment outcome in the last decade.
Conclusions
This article presents a near complete overview of all available
data concerning SNC. It offers a basic understanding of their clini-
cal behavior and a general direction for deciding on a treatment
strategy. While the nature of the data does not allow for definite
treatment guidelines, certain overall conclusions and recommen-
dations can be made.
It is clear that a proper histological diagnosis with emphasis on
differentiation grade is of paramount importance in predicting
prognosis and treatment response in SNC. Well and moderately
differentiated SNC perform significantly better and may require a
less aggressive treatment approach than their poorly differentiated
counterparts. However, no strong recommendations can be made
in this regard, due to semantic deficiencies in the literature. There-
fore, we strongly advocate the application of a uniform classifica-
tion system for neuroendocrine carcinoma of the head and neck.
As we are unable to reliably infer the relationship between
tumor stage on presentation and survival from our data, we feel
caution is justified in taking a more conservative approach in treat-
ing patients with early stage disease.
Surgery should be the cornerstone of any treatment strategy
with curative intent, supplemented by radiotherapy in poorly
(and perhaps moderately) differentiated subtypes. Chemotherapy
does not appear to contribute to survival.
Overcoming the limitations of this study would require a long
term multi-center clinical trial. Until such a study is performed
we have to rely on fragmented data such as presented in this paper.
Therefore, we encourage institutions to keep publishing their expe-
riences with these rare neoplasms.Conflict of interest statement
None declared.
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